<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-149616" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mohs Micrographic Surgery Evaluation and Treatment of Dermatofibrosarcoma Protuberans</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Siddiqui</surname>
            <given-names>Fahad S.</given-names>
          </name>
          <aff>Kansas City University/ADCS Dermatology Residency</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sathe</surname>
            <given-names>Nishad C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leavitt</surname>
            <given-names>Adam</given-names>
          </name>
          <aff>Kansas City University/ADCS Orlando</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Fahad Siddiqui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nishad Sathe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adam Leavitt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-149616.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive soft tissue skin tumor.<xref ref-type="bibr" rid="article-149616.r1">[1]</xref> DFSP originates from the dermal layer of the skin, typically manifesting as a slow-growing, indurated plaque or nodule.<xref ref-type="bibr" rid="article-149616.r2">[2]</xref> The tumor's predilection for the trunk and proximal extremities reflects its origin in the reticular dermis.<xref ref-type="bibr" rid="article-149616.r3">[3]</xref>&#x000a0;DFSP rarely metastasizes. However, some tumors show high-grade sarcomatous change, potentially impacting evaluation and treatment.<xref ref-type="bibr" rid="article-149616.r4">[4]</xref> DFSP spreads locally along tissue planes, infiltrating adjacent structures while respecting tissue boundaries. Metastasis to regional lymph nodes or distant sites is rare but usually involves high-grade or fibrosarcomatous transformation. Micrographic dermatologic surgery (MDS) is vital in achieving tumor-free margins while preserving function and cosmesis.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="38648936">[5]</ext-link>&#x000a0;MDS, including Mohs micrographic surgery (MMS) and other peripheral and deep en-face margin assessment techniques, has become a cornerstone in managing DFSP, offering precise tumor removal while sparing healthy tissue.<xref ref-type="bibr" rid="article-149616.r5">[6]</xref></p>
      </sec>
      <sec id="article-149616.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of&#x000a0;DFSP remains incompletely understood, with no definitive causative factors identified. However, several genetic and environmental factors have been implicated in its pathogenesis.<xref ref-type="bibr" rid="article-149616.r6">[7]</xref>&#x000a0;Genetic aberrations play a central role in DFSP development, with over 90% of cases characterized by a specific chromosomal translocation involving chromosomes 17 and 22. This translocation, t(17;22)(q22;q13), results in the fusion of the type&#x000a0;I &#x003b1;1 collagen (<italic toggle="yes">COL1A1</italic>) and platelet-derived growth factor-&#x003b2;&#x000a0;(<italic toggle="yes">PDGF-&#x003b2;</italic>) genes, leading to constitutive activation of the PDGF-&#x003b2; receptor.<xref ref-type="bibr" rid="article-149616.r7">[8]</xref> Activation of this receptor promotes cell proliferation and angiogenesis, contributing to DFSP tumorigenesis.</p>
        <p>Besides&#x000a0;genetic predisposition, environmental factors such as ultraviolet (UV) radiation exposure and trauma have been proposed as potential contributors to DFSP development.<xref ref-type="bibr" rid="article-149616.r8">[9]</xref> UV radiation-induced deoxyribonucleic acid (DNA) damage may exacerbate genomic instability, facilitating the accumulation of genetic mutations conducive to DFSP progression.<xref ref-type="bibr" rid="article-149616.r9">[10]</xref> Trauma, particularly repetitive injury or scarring, has been suggested to trigger DFSP growth in predisposed individuals, although the exact mechanisms remain unclear.</p>
      </sec>
      <sec id="article-149616.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>DFSP accounts for approximately 1% of all soft tissue sarcomas in the United States, translating to an estimated annual incidence of 4.1 cases per million individuals.&#x000a0;The condition typically affects adults in their 3rd to 5th decades of life, with a median age at diagnosis ranging from 30 to 40 years. However, cases have been reported across all age groups, including pediatric and older adult populations. Studies have not demonstrated a clear sex predominance. Racial and ethnic disparities in DFSP incidence have been noted, with almost double the incidence in Black patients compared to White patients.<xref ref-type="bibr" rid="article-149616.r10">[11]</xref> Internationally, DFSP incidence rates vary across different regions and populations. Limited population-based studies and registries hinder the comprehensive assessment of global DFSP epidemiology.</p>
      </sec>
      <sec id="article-149616.s4" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathologically,&#x000a0;DFSP is characterized by spindle-shaped fibroblast-like cells arranged in a storiform or cartwheel pattern within the dermis.<xref ref-type="bibr" rid="article-149616.r11">[12]</xref> These cells typically exhibit low-to-moderate nuclear atypia and scant cytoplasm (see&#x000a0;<bold>Image.</bold> Dermatofibrosarcoma Protuberans Histology).<xref ref-type="bibr" rid="article-149616.r12">[13]</xref> Collagen deposition and myxoid changes may also be observed within the tumor stroma. Immunohistochemical staining often shows positivity for CD34, a marker commonly associated with DFSP.<xref ref-type="bibr" rid="article-149616.r12">[13]</xref></p>
        <p>Despite its benign histological appearance, DFSP is locally aggressive, tends to infiltrate surrounding tissues, and recurs if not adequately excised with clear margins. Rarely, DFSP undergoes fibrosarcomatous transformation, characterized by increased cellularity, nuclear pleomorphism, and mitotic activity, indicating a more aggressive phenotype (see&#x000a0;<bold>Image.</bold>&#x000a0;Fibrosarcomatous Change).<xref ref-type="bibr" rid="article-149616.r13">[14]</xref></p>
      </sec>
      <sec id="article-149616.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>DFSP presents variably, often posing diagnostic challenges due to its insidious growth pattern and nonspecific symptoms. Patients commonly report a slow-growing, painless, firm, indurated skin plaque or nodule, which may mimic benign lesions such as dermatofibroma or keloid scars (see&#x000a0;<bold>Image.&#x000a0;</bold>Dermatofibrosarcoma Protuberans, Right Lower Extremity).<xref ref-type="bibr" rid="article-149616.r14">[15]</xref></p>
        <p>DFSP most commonly occurs on the trunk, proximal extremities, head, and neck.<xref ref-type="bibr" rid="article-149616.r15">[16]</xref><xref ref-type="bibr" rid="article-149616.r16">[17]</xref><xref ref-type="bibr" rid="article-149616.r17">[18]</xref>&#x000a0;The lesion typically arises in the skin's dermal layer and may exhibit a reddish-brown or violaceous hue, although coloration can vary.&#x000a0;The typical DFSP lesion&#x000a0;is characterized by its firm consistency and tendency to protrude above the skin surface, thus&#x000a0;its protuberant appearance. The lesion may be well-demarcated or ill-defined, with a rubbery or fibrotic texture upon palpation. Advanced DFSP may also exhibit overlying telangiectasias or ulceration.<xref ref-type="bibr" rid="article-149616.r18">[19]</xref> Tumor diameter can range from 0.5 cm to greater than 10 cm, with an average of 2 to 3.5 cm.<xref ref-type="bibr" rid="article-149616.r19">[20]</xref><xref ref-type="bibr" rid="article-149616.r20">[21]</xref></p>
      </sec>
      <sec id="article-149616.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The evaluation of&#x000a0;DFSP typically involves a combination of clinical assessment, histopathological examination, and&#x000a0;imaging studies to establish a definitive diagnosis and guide treatment planning. Much of the evaluation is guided by National Comprehensive Cancer Network guidelines for DFSP.&#x000a0;Interprofessional consultation in treatment centers experienced in DFSP should be considered, especially for patients with large or recurrent DFSP.</p>
        <p>
<bold>Clinical Evaluation</bold>
</p>
        <p>Clinical examination remains the cornerstone of DFSP evaluation, with thorough inspection and palpation of the lesion to assess its size, location, consistency, and associated symptoms.&#x000a0;Other relevant history and physical examination, including family history, social history, personal medical history, and a complete skin examination, are pertinent in evaluating a patient with a lesion suspicious of DFSP.&#x000a0;Dermoscopy may aid the clinical diagnosis by revealing characteristic features, such as a pigment network, linear vessels, and a central, white, scar-like area.<xref ref-type="bibr" rid="article-149616.r21">[22]</xref> However, definitive diagnosis requires histopathological confirmation through biopsy or surgical excision, specifically a punch, incisional, or core biopsy, to ensure adequate tissue sampling through the deeper subcutaneous layer.</p>
        <p>
<bold>Histopathologic Evaluation</bold>
</p>
        <p>Histopathological examination of a biopsy specimen is essential for diagnosing DFSP and differentiating it from other cutaneous neoplasms. Qualified and experienced pathologists should evaluate lesions suspicious for DFSP. The characteristic histological features of DFSP include spindle-shaped fibroblast-like cells arranged in a storiform or cartwheel pattern within the dermis, often accompanied by collagen deposition and myxoid changes. Immunohistochemical staining for CD34 is typically positive in DFSP, supporting the diagnosis. Staining negative for factor XIIIa would&#x000a0;differentiate DFSP from its benign counterpart.<xref ref-type="bibr" rid="article-149616.r22">[23]</xref></p>
        <p>A nondiagnostic specimen should be rebiopsied without undermining to prevent difficulty interpreting reexcisions. Fluorescent in situ hybridization for platelet-derived growth factor receptor (PDGFR) translocation should be performed for equivocal lesions.&#x000a0;Polymerase chain reaction and&#x000a0;conventional&#x000a0;cytogenetics may also be used to confirm characteristic genetic changes.<xref ref-type="bibr" rid="article-149616.r23">[24]</xref></p>
        <p>Debulking specimens from the biopsy should be evaluated thoroughly to rule out fibrosarcomatous transformation. If observed, the lesion will need further&#x000a0;evaluation as&#x000a0;soft tissue sarcoma for&#x000a0;multimodal therapy.&#x000a0;Lesions&#x000a0;with fibrosarcomatous changes are considered soft tissue sarcomas of the extremity, body wall, head, or neck.&#x000a0;Besides adequate imaging, a core needle (preferred) or incisional biopsy should be performed. Ancillary diagnostic methods may be needed. Additional imaging may be indicated in select patients with genetic tumor syndromes, including patients with neurofibromatosis, Li-Fraumeni syndrome, and hereditary nonpolyposis colorectal cancer syndrome (ie, Lynch syndrome).</p>
        <p>
<bold>Radiographic Evaluation</bold>
</p>
        <p>Radiographic imaging, such as ultrasonography, magnetic resonance imaging (MRI),&#x000a0;and computed tomography (CT), may be warranted to assess tumor depth, size, and extent of local invasion, particularly for&#x000a0;further&#x000a0;evaluation&#x000a0;of inconclusive cases or&#x000a0;planning surgical intervention. MRI is the preferred imaging modality for evaluating DFSP, offering superior soft tissue contrast resolution and multiplanar imaging capabilities.<xref ref-type="bibr" rid="article-149616.r24">[25]</xref> MRI defines the tumor's size, extent, and association with neighboring neuromuscular structures and bone.&#x000a0;MRI is thus a useful modality for preoperative and postoperative evaluation, especially if extensive subcutaneous extension of the DFSP is evident.<xref ref-type="bibr" rid="article-149616.r25">[26]</xref>&#x000a0;Staging evaluations, including chest radiography or CT scans, may also be recommended to assess for metastatic disease in high-risk cases or in the presence of suspicious clinical findings. However, routine staging imaging is not typically indicated for localized DFSP without evidence of advanced disease or concerning symptoms.</p>
      </sec>
      <sec id="article-149616.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>DFSP management requires a comprehensive approach aimed at achieving complete tumor excision while minimizing morbidity and reducing the risk of recurrence. Treatment modalities encompass surgical, medical, and, in select cases, adjuvant therapies tailored to the individual patient's disease characteristics and clinical presentation.</p>
        <p>Surgical excision should be performed with&#x000a0;MDS with peripheral and deep en-face margin assessment. If the tumor is borderline or unresectable, tumor mutation analysis and neoadjuvant imatinib should be considered.<xref ref-type="bibr" rid="article-149616.r26">[27]</xref>&#x000a0;Regular monitoring should be initiated for tumors with negative margins, while those with positive margins should be reexcised where possible.&#x000a0;When&#x000a0;positive margins remain, or surgery becomes infeasible, patients should undergo&#x000a0;interprofessional&#x000a0;evaluation and management, which may include radiation therapy or other medical interventions.<xref ref-type="bibr" rid="article-149616.r27">[28]</xref></p>
        <p>
<bold>Surgical Interventions</bold>
</p>
        <p>Surgical excision remains the treatment mainstay for localized DFSP, with the primary goal of achieving tumor-free margins while preserving function and cosmesis.&#x000a0;MDS, including MMS or other forms of peripheral and deep en-face margin assessment,&#x000a0;has emerged as a preferred surgical technique for managing DFSP, offering precise tumor removal with high cure rates while sparing healthy tissue.<xref ref-type="bibr" rid="article-149616.r28">[29]</xref>&#x000a0;MMS involves serial excision and examination of tissue layers under microscopy until tumor-free margins are achieved, minimizing the risk of recurrence and maximizing tissue conservation, particularly in cosmetically sensitive areas or tumors with ill-defined borders.</p>
        <p>Notably,&#x000a0;DFSP can occasionally exhibit "skip growth" with neoplastic cells extending past the clinically apparent tumor margins. This phenomenon may lead to incomplete excision of the tumor despite the meticulous layer-by-layer strategy characteristic of MMS. Extensive undermining postsurgical excision is also not recommended, as it could potentially seed malignant cells if the tumor is not completely resected. This measure may also complicate the interpretation of subsequent reexcisions. Tumors initially excised with positive margins or those that have relapsed&#x000a0;warrant&#x000a0;further excision to attain clear margins whenever feasible.</p>
        <p>For surgical treatment of DFSP, tumor bed excision should be based on tumor infiltration depth. Superficial (stages I&#x000a0;and&#x000a0;IIA) tumors may be excised without including the underlying fascia. In contrast, excision of the muscle or periosteum's investing fascia is recommended for deeper&#x000a0;(stage IIB) tumors.&#x000a0;Due to limited space and complex structures, the digits pose a challenge for wide local excision (WLE). MMS appears to be the more appropriate treatment modality for DFSP of the digits, keeping in mind that periosteal involvement may necessitate partial or total amputation of the digit to achieve tumor-free margins.<xref ref-type="bibr" rid="article-149616.r29">[30]</xref></p>
        <p>Reconstruction should be postponed until a thorough examination confirms that all peripheral and deep margins are negative. Presently, no consensus exists on the ideal width of margins. Results from a 1997 study of 58 patients with primary and recurrent DFSP treated with MMS found that 70% of patients had positive margins with a 1 cm margin, 39.7% with a 2 cm margin, 15.5% with a 3 cm margin, and 5.2% with a 5 cm margin.<xref ref-type="bibr" rid="article-149616.r30">[31]</xref></p>
        <p>Further, results from a 2022 single-center study of 222 DFSP cases treated with MMS found that an average of 1.47 stages and a minimum margin of 1.23 cm were required for tumor clearance.&#x000a0;Tumors located in the head and neck region necessitated more stages and a significantly wider margin. Tumor size&#x000a0;also showed a positive correlation with time to diagnosis, the patient&#x02019;s age, and the number of stages taken.<xref ref-type="bibr" rid="article-149616.r31">[32]</xref></p>
        <p>The literature has shown significant variation in local recurrence rates with different surgical margins.&#x000a0;Postponing reconstruction after MMS is advised for cases necessitating extensive resection or tissue manipulation. This approach enables confirmation of negative margins before proceeding with reconstruction.<xref ref-type="bibr" rid="article-149616.r32">[33]</xref> Reconstruction options include rotational flaps or full- or split-thickness skin grafts. The choice of reconstruction depends on multiple factors, including the defect's size, depth, and location.</p>
        <p>Slow Mohs, also known as paraffin MMS, is preferred for evaluating tumors with high-risk histological characteristics like DFSP. This modified MMS method utilizes paraffin-embedded permanent sections and requires at least 24 to 48 hours of processing time.<xref ref-type="bibr" rid="article-149616.r33">[34]</xref>&#x000a0;In contrast to conventional MMS, paraffin MMS enables tissue morphology preservation, complete tumor staging, residual tumor tissue identification, and the ability to perform immunohistochemistry studies.<xref ref-type="bibr" rid="article-149616.r34">[35]</xref><xref ref-type="bibr" rid="article-149616.r35">[36]</xref> However, given the apparent practical advantages of frozen MMS, both techniques may be considered effective.</p>
        <p>
<bold>Appropriate Use Criteria</bold>
</p>
        <p>According to the MMS appropriate use criteria, MMS is appropriate for DFSP in all locations and patient types.<xref ref-type="bibr" rid="article-149616.r36">[37]</xref>&#x000a0;In cases where MMS is not feasible or is contraindicated, WLE with 2- to 3-cm margins extending to the fascia may be performed, followed by a histopathological examination to confirm clear margins.<xref ref-type="bibr" rid="article-149616.r37">[38]</xref>&#x000a0;MMS has demonstrated a lower local recurrence rate than WLE when utilized for DFSP.<xref ref-type="bibr" rid="article-149616.r38">[39]</xref><xref ref-type="bibr" rid="article-149616.r39">[40]</xref><xref ref-type="bibr" rid="article-149616.r40">[41]</xref><xref ref-type="bibr" rid="article-149616.r41">[42]</xref>&#x000a0;Conclusions from a 2024 meta-analysis of 136 cases revealed that the disease-specific mortality rate was not significantly different between patients treated with MMS vs WLE for DFSP. However, for recurrent tumors, the MMS treatment cohort exhibited a statistically significant reduction in disease-specific mortality compared to patients treated with WLE.<xref ref-type="bibr" rid="article-149616.r42">[43]</xref> MMS is also less costly than WLE for all surgical sites.<xref ref-type="bibr" rid="article-149616.r43">[44]</xref></p>
        <p>
<bold>Potential Drawbacks</bold>
</p>
        <p>Drawbacks of MMS include the potential for tumor cells to be mistaken for normal dermal spindle cells in frozen sections and the high CD34-staining variability of frozen sections. Some authors question the reliability of this technique altogether.<xref ref-type="bibr" rid="article-149616.r44">[45]</xref><xref ref-type="bibr" rid="article-149616.r45">[46]</xref> This concern may be addressed by&#x000a0;excising&#x000a0;an extra layer and sending it for permanent paraffin-embedded assessment once negative frozen margins are achieved.&#x000a0;However, clearing deep margins can be challenging if the tumor has invaded the underlying fascia or muscle.</p>
        <p>A&#x000a0;study of 40 cases demonstrated that 43% of patients needed resection of fascia, muscle, or periosteum to achieve tumor clearance.<xref ref-type="bibr" rid="article-149616.r46">[47]</xref>&#x000a0;MMS procedures can also be intricate, time-consuming, and necessitate extensive procedures for patients and subsequent reconstruction.<xref ref-type="bibr" rid="article-149616.r47">[48]</xref> For&#x000a0;tumors&#x000a0;invading&#x000a0;deep structures,&#x000a0;eg, bone, nerves, major blood vessels, MMS may be used for marginal surfaces with an&#x000a0;interprofessional&#x000a0;discussion of nonvisualized areas.</p>
        <p>
<bold>Recurrence and Metastasis</bold>
</p>
        <p>Recurrence&#x000a0;warrants&#x000a0;tumor re-resection. Radiation therapy should be considered if it was not previously used and resection is infeasible.&#x000a0;Imatinib therapy may be used if the disease is unresectable or resection cannot be performed due to anatomic restrictions. Patients with metastatic lesions should have interprofessional consultations to determine the best individualized treatment approach, possibly including surgery.&#x000a0;Radiation therapy is not recommended if MDS is used. Otherwise, radiation therapy may be considered for surgical cases rendering positive margins if not previously used and re-resection is infeasible.</p>
        <p>DFSP&#x000a0;with fibrosarcomatous differentiation (DFSP-FS) is a highly aggressive DFSP subtype with 50% local recurrence and 10% to 15% metastasis rates.<xref ref-type="bibr" rid="article-149616.r48">[49]</xref><xref ref-type="bibr" rid="article-149616.r49">[50]</xref> DFSP-FS treatment includes WLE with clear margins or MMS for stages IA, IB, II,&#x000a0;and&#x000a0;III disease.&#x000a0;Other adjuvant therapies (eg, systemic or radiation therapy) may also be needed to achieve tumor clearance.&#x000a0;Resectable stage-II, -III,&#x000a0;and&#x000a0;-IV disease with unacceptable functional outcomes or unresectable primary disease&#x000a0;may require&#x000a0;radiation therapy, chemoradiation, systemic therapy, isolated limb perfusion/infusion, or amputation/radical resection.<xref ref-type="bibr" rid="article-149616.r50">[51]</xref></p>
        <p>Synchronous stage IV disease with oligometastases with limited tissue bulk&#x000a0;amenable to local therapy should undergo similar treatments for earlier-stage disease. However, patients&#x000a0;with diffuse metastases may also consider metastasectomy, stereotactic body radiation therapy, ablation, embolization (for nonlung metastases), observation, or palliative care.&#x000a0;These same treatments are considered for metastatic disease and recurrences.<xref ref-type="bibr" rid="article-149616.r51">[52]</xref></p>
        <p>
<bold>Adjuvant Therapy</bold>
</p>
        <p>Adjuvant therapies, such as radiotherapy or systemic therapy, may be considered in select DFSP cases with high-risk features, including large tumor size, positive margins, and unresectability. Radiotherapy may be employed as adjuvant therapy following surgical excision to reduce the risk of local recurrence, particularly in cases with close or positive margins. Systemic therapies, including imatinib, a tyrosine kinase inhibitor targeting the&#x000a0;platelet-derived growth factor-&#x003b2; receptor, may be considered in unresectable, metastatic, or recurrent DFSP.&#x000a0;However,&#x000a0;further research is needed to define optimal treatment strategies and long-term outcomes.<xref ref-type="bibr" rid="article-149616.r52">[53]</xref></p>
      </sec>
      <sec id="article-149616.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Key clinical and histopathologic differential diagnoses that must be considered when evaluating for&#x000a0;DFSP include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dermatofibroma</p>
          </list-item>
          <list-item>
            <p>Schwannoma</p>
          </list-item>
          <list-item>
            <p>Cutaneous neurofibroma</p>
          </list-item>
          <list-item>
            <p>Solitary fibrous tumor</p>
          </list-item>
          <list-item>
            <p>Intradermal spindle cell lipoma</p>
          </list-item>
          <list-item>
            <p>Spindle cell/desmoplastic melanoma</p>
          </list-item>
        </list>
        <p>While these diagnoses should be considered in the differential diagnosis, each entity has features distinguishing it from DFSP.<xref ref-type="bibr" rid="article-149616.r12">[13]</xref>&#x000a0;For example, dermatofibroma stains negative for CD34, spindle cell lipomas are S100-positive, and spindle cell melanoma expresses S100, SOX-10, and&#x000a0;glial fibrillary acidic protein. Accurate diagnosis requires careful clinical evaluation and histopathological examination facilitated by collaboration among dermatologists, dermatopathologists, and surgical oncologists to ensure appropriate management and optimize patient outcomes.</p>
      </sec>
      <sec id="article-149616.s9" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>Radiation therapy plays a significant role in DFSP management, particularly as adjuvant therapy following surgical excision in cases with high-risk features or positive margins. Adjuvant radiation therapy should be considered for resected tumors with positive margins or gross disease.&#x000a0;Doses typically range from 50 to 60 Gy for indeterminate or positive margins and up to 66 Gy for positive margins or gross tumor, given in 2-Gy fractions daily. The treatment can extend 3 to 5 cm beyond surgical margins when feasible.<xref ref-type="bibr" rid="article-149616.r27">[28]</xref>&#x000a0;Radiation therapy is recommended for negative margins only if&#x000a0;MDS is not used. The same radiation therapy is recommended for positive margins if relapse or metastasis occurs previous radiation therapy has not been administered, or surgery is infeasible.<xref ref-type="bibr" rid="article-149616.r53">[54]</xref><xref ref-type="bibr" rid="article-149616.r54">[55]</xref></p>
        <p>Studies show that adjuvant radiation therapy following surgical excision significantly reduces the risk of local recurrence and may improve long-term outcomes in patients with DFSP.&#x000a0;However, the optimal timing, dose, and fractionation of radiation therapy remain areas of ongoing research and debate. Some authors recommend that 60 Gy for indeterminate/microscopic positive margins and 70 Gy for macroscopic positive margins should be utilized. Individual doses may be administered 5 times a week at 2 Gy daily.&#x000a0;Additionally, ongoing clinical trials are investigating novel radiation techniques, such as intensity-modulated radiation therapy (IMRT) and proton beam therapy, to improve treatment efficacy and minimize toxicity in patients with DFSP.</p>
        <p>For DFSP with fibrosarcomatous change, multiple radiation therapy strategies are suggested based on the type of treatment. Neoadjuvant radiation therapy should include a preoperative dose of 50 to 50.4 Gy (1.8-2 Gy per fraction) using electron beam therapy, 3-dimensional conformal radiation therapy, IMRT, or proton beam therapy with imaging. An additional 14 to 20 Gy may be used with fractionated external beam radiation therapy (EBRT) or brachytherapy if appropriate.<xref ref-type="bibr" rid="article-149616.r55">[56]</xref><xref ref-type="bibr" rid="article-149616.r56">[57]</xref></p>
        <p>Adjuvant radiation therapy should be performed on postoperative disease, with EBRT doses of 50 to 50.4 Gy&#x000a0;at 1.8 to 2 Gy per fraction and a 10- to 16-Gy boost as tolerated.&#x000a0;If brachytherapy is&#x000a0;combined with EBRT, 16- to 20-Gy or 14- to 16-Gy brachytherapy with 50-Gy&#x000a0;EBRT should be used for positive margins, while 45-Gy or 36-Gy brachytherapy (3.6 Gy twice daily for 10 fractions in 5 days) should be used for tumors with negative margins.<xref ref-type="bibr" rid="article-149616.r57">[58]</xref><xref ref-type="bibr" rid="article-149616.r58">[59]</xref>&#x000a0;For definitive radiation therapy in unresectable disease, initial doses of 50 Gy with a boost of 63 Gy may be used, though higher doses up to 70 to 80 Gy may be considered based on tolerance.<xref ref-type="bibr" rid="article-149616.r59">[60]</xref></p>
      </sec>
      <sec id="article-149616.s10" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Medical oncology plays a crucial role in treating DFSP, particularly when surgical intervention is infeasible, or the tumor recurrence risk is high.&#x000a0;A significant advancement in the medical management of DFSP is targeted therapy, particularly with imatinib mesylate. Imatinib, a tyrosine kinase inhibitor, has shown remarkable efficacy in&#x000a0;managing DFSP, especially&#x000a0;when complete surgical resection is challenging due to tumor location, size, or involvement of critical structures. The drug inhibits the activity of specific tyrosine kinases, including platelet-derived growth factor receptors, which are often overexpressed in DFSP.</p>
        <p>Clinical studies have demonstrated the effectiveness of imatinib in controlling DFSP growth, inducing tumor regression, and improving progression-free survival rates.<xref ref-type="bibr" rid="article-149616.r60">[61]</xref>&#x000a0;The decision to initiate imatinib therapy is based on various factors, including disease extent, tumor size, location, and metastasis. Treatment regimens typically involve oral administration at a recommended dose of 400 to 800 mg daily,&#x000a0;adjusted to&#x000a0;individual response and tolerance.&#x000a0;Other&#x000a0;tyrosine kinase inhibitors,&#x000a0;such as&#x000a0;sunitinib and sorafenib,&#x000a0;have been used as&#x000a0;additional treatment options for DFSP.<xref ref-type="bibr" rid="article-149616.r61">[62]</xref></p>
        <p>For DFSP with fibrosarcomatous change, medical therapy depends on whether&#x000a0;a regimen&#x000a0;is used as&#x000a0;neoadjuvant/adjuvant, first-line,&#x000a0;or&#x000a0;subsequent-line therapy.&#x000a0;The preferred regimen&#x000a0;for neoadjuvant/adjuvant therapy includes ifosfamide and mesna with either doxorubicin or epirubicin. Gemcitabine, docetaxel, or trabectedin may be useful in certain circumstances.<xref ref-type="bibr" rid="article-149616.r62">[63]</xref><xref ref-type="bibr" rid="article-149616.r63">[64]</xref> For first-line therapy&#x000a0;of&#x000a0;advanced or metastatic disease, the preferred regimen&#x000a0;may include combinations of doxorubicin, epirubicin, dacarbazine, ifosfamide, larotrectinib, or entrectinib. Gemcitabine, docetaxel, pazopanib, trabectedin, and selpercatinib (RET fusion-positive tumors) may be useful in select circumstances.<xref ref-type="bibr" rid="article-149616.r64">[65]</xref><xref ref-type="bibr" rid="article-149616.r65">[66]</xref>&#x000a0;For subsequent-line therapy&#x000a0;of&#x000a0;advanced or metastatic disease,&#x000a0;the preferred regimen may include combinations of pazopanib, eribulin, trabectedin, gemcitabine, docetaxel, dacarbazine, ifosfamide, temozolomide, vinorelbine, and regorafenib. Vinorelbine with gemcitabine, pazopanib with gemcitabine, pembrolizumab, nivolumab with ipilimumab, or cabozantinib may be useful in certain circumstances.<xref ref-type="bibr" rid="article-149616.r66">[67]</xref><xref ref-type="bibr" rid="article-149616.r67">[68]</xref></p>
      </sec>
      <sec id="article-149616.s11" sec-type="Staging">
        <title>Staging</title>
        <p>DFSP staging currently lacks a standard system. However,&#x000a0;a modified staging system has been proposed by Hao et al, outlined below.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage I </bold>tumors are nonprotuberant lesions that may include atrophic/sclerotic plaques, maculae, or small nodules.</p>
          </list-item>
          <list-item>
            <p><bold>Stage II</bold>&#x000a0;includes protuberant primary tumors, further divided into IIA and IIB.
<list list-type="bullet"><list-item><p>Stage IIA tumors are superficial and do not invade the underlying fascia.</p></list-item><list-item><p>Stage IIB tumors are deeper, either located superficial to the fascia with deeper infiltration or occurring entirely beneath the superficial fascia.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Stage III</bold> tumors include those with lymph node metastasis.</p>
          </list-item>
          <list-item>
            <p><bold>Stage IV </bold>tumors include those with metastasis to distant organs.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-149616.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of DFSP&#x000a0;is generally favorable, with a low risk of metastasis and high rates of long-term survival, mainly when diagnosed and treated early. The overall prognosis is primarily influenced by factors such as tumor size, depth of invasion, margin status, and presence of metastasis. After surgical excision with margin evaluation, DFSP has 5- and 10-year recurrence-free survival rates of 86% and 76%, respectively.&#x000a0;Male sex, Black race, head/limb tumor location, increased tumor size, fibrosarcomatous transformation, positive margins, and advanced age are all associated with a decreased overall survival rate.&#x000a0;Recurrence rates after excision range from 20% to 50%, with an average time to recurrence of 32 to 38 months.&#x000a0;Long-term surveillance every 6 to 12 months is thus encouraged.</p>
      </sec>
      <sec id="article-149616.s13" sec-type="Complications">
        <title>Complications</title>
        <p>MMS&#x000a0;is highly effective&#x000a0;in&#x000a0;treating DFSP. However,&#x000a0;MMS carries certain risks, as with&#x000a0;other&#x000a0;surgical procedures.&#x000a0;Possible complications include seeding tumor cells, delayed wound healing, wound dehiscence, infection, and cosmetic concerns such as noticeable scars or skin texture changes. Depending on tumor size and location, MMS may also lead to functional impairment or limitations in range of motion, particularly in areas involving critical anatomical structures.</p>
        <p>Despite its high cure rates, the risk of local recurrence following MMS remains, especially in cases with close or positive surgical margins. DFSP can occasionally exhibit skip growth,&#x000a0;with neoplastic cells extending beyond the clinically apparent tumor margins. This occurrence&#x000a0;produces microscopic disease foci that can evade initial detection. This characteristic poses a challenge for MMS, as the focal clusters of skipped tumor cells may remain undetected and lead to incomplete excision, increasing the risk of local recurrence. Rare complications&#x000a0;include&#x000a0;nerve damage, bleeding, hematoma formation, and scar contracture. Mitigating these risks requires careful preoperative evaluation, meticulous surgical technique, and diligent postoperative care, emphasizing the importance of close communication between the surgical team and the patient to optimize outcomes and address concerns following MMS for DFSP.</p>
      </sec>
      <sec id="article-149616.s14" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Postoperative care&#x000a0;following MMS for DFSP is essential to promote wound healing, prevent complications, and optimize functional and cosmetic outcomes. Patients should be instructed to keep the surgical site clean and dry, avoiding excessive manipulation or trauma to the area. Wound care instructions, including dressing changes and wound monitoring, should be provided, and close follow-up should be scheduled to assess healing progress and monitor for signs of infection or other complications.</p>
        <p>Depending on the size and location of the tumor, patients may benefit from physical therapy or rehabilitation exercises to restore range of motion, strength, and function in affected areas. Early mobilization and gentle stretching exercises can help prevent stiffness and promote tissue healing, particularly when DFSP involves critical anatomical structures or requires extensive tissue excision.</p>
        <p>Cosmetic concerns following MMS for DFSP should be addressed through appropriate wound management and scar care techniques. Patients should be educated on scar massage, silicone gel application, and sun protection measures to minimize scar hypertrophy, pigmentation changes, and other aesthetic issues. Long-term follow-up care is essential to monitor for signs of local recurrence, assess functional and cosmetic outcomes, and address any concerns or complications that may arise. Patients should be encouraged to maintain regular dermatologic surveillance every 6 to 12 months to detect any potential recurrence or new skin lesions early.</p>
      </sec>
      <sec id="article-149616.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education plays a crucial role in the deterrence and management of DFSP. Raising awareness among patients about the signs and symptoms of DFSP is essential, emphasizing the importance of early detection and prompt medical evaluation for any suspicious skin lesions. Patients should be educated about DFSP risk factors, including previous trauma or surgical scars, and encouraged to perform regular skin self-examinations to monitor for changes in existing lesions or the development of new ones.</p>
        <p>Furthermore, patients should be informed about the significance of seeking care from dermatologists or healthcare providers with expertise in skin cancer diagnosis and management. Patients should understand the diagnostic and treatment options available for DFSP, including MMS and WLE, and be actively involved in shared decision-making regarding their care. Sun protection measures, including sunscreen, protective clothing, and seeking shade during peak UV hours, should also be emphasized to reduce the risk of developing DFSP and other malignancies. Additionally, patients should be educated about the importance of regular dermatologic surveillance and long-term follow-up care post-DFSP treatment to monitor for recurrence and ensure optimal outcomes.</p>
      </sec>
      <sec id="article-149616.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Successfully managing DFSP with MMS necessitates a highly coordinated, interprofessional healthcare team approach. Physicians, including dermatologic surgeons and surgical oncologists, lead the team and apply their expertise in skin cancer diagnosis and MMS techniques. Clinicians must possess advanced procedural skills, meticulous attention to detail, and sound clinical judgment to ensure complete tumor removal while preserving surrounding healthy tissue.</p>
        <p>Referral to an interdisciplinary oncology team (tumor board) with broad knowledge and experience with DFSP is important, especially in fibrosarcomatous DFSP cases.&#x000a0;Collaborative multidisciplinary management proves beneficial for managing infiltrative DFSP of the head and neck and large tumors on the trunk. In this approach, the Mohs surgeon conducts tumor mapping and histologic examination of margins in coordination with another ablative surgeon.<xref ref-type="bibr" rid="article-149616.r68">[69]</xref></p>
        <p>Results from a 2023 study regarding socioeconomic factors associated with MMS for DFSP demonstrated that MMS was more commonly performed at academic centers, likely due to increased resources and access to&#x000a0;interprofessional&#x000a0;experts.&#x000a0;Higher incomes were also found to be predictive of MMS, revealing potential healthcare disparities. Advanced practitioners, such as physician assistants and nurse practitioners, collaborate closely with physicians to provide comprehensive patient care throughout the MMS process. These providers play key roles in patient assessment, intraoperative assistance, wound care, and postoperative follow-up, serving as liaisons between patients and the healthcare team.</p>
        <p>Nurses are integral members of the MMS team, responsible for preoperative preparation, intraoperative assistance, and postoperative care. Nursing staff members&#x000a0;ensure patient safety, comfort, and adherence to infection control protocols during MMS procedures. Nurses also provide patient education, wound assessment, and symptom management, facilitating optimal recovery and outcomes.</p>
        <p>Pharmacists contribute expertise in medication management, ensuring appropriate perioperative pharmacotherapy and minimizing potential drug interactions or adverse effects. These providers&#x000a0;collaborate with the healthcare team to optimize pain management, prophylactic antibiotic use, and wound healing&#x02014;promoting patient safety and treatment efficacy.</p>
        <p>Ethical considerations, including informed consent, patient autonomy, and beneficence, guide healthcare team members in providing patient-centered care during MMS for DFSP. Respect for patient preferences, cultural sensitivity, and confidentiality fosters trust and rapport between patients and the healthcare team, enhancing patient satisfaction and treatment adherence. By leveraging their collective skills, expertise, and resources, the healthcare team can optimize patient-centered care, minimize complications, and achieve favorable outcomes. Collaborative efforts among healthcare professionals facilitate efficient procedural workflows, streamline patient care pathways, and promote a culture of excellence in DFSP management.</p>
      </sec>
      <sec id="article-149616.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=149616&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=149616">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/mohs-micrographic-surgery-evaluation-and-treatment-of-dermatofibrosarcoma-protuberans/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=149616">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/149616/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=149616">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-149616.s18">
        <fig id="article-149616.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Dermatofibrosarcoma Protuberans Histology.&#x000a0;Dermatofibrosarcoma protuberans (DFSP) is characterized by spindle cells with a storiform-to-whorled pattern (hematoxylin and eosin, x 100 magnification). Contributed by Haitham Saleh, MSc</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2024-04-27__at__11.44.26__AM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-149616.s19">
        <fig id="article-149616.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Fibrosarcomatous Change. Dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous change, thigh.&#x000a0;Hematoxylin-and-eosin-stained&#x000a0;DFSP with fibrosarcomatous component indicated by black arrows at 100 times magnification. Used with permission via Creative Commons license (open-access article) from:&#x000a0;Kim SM, Rha EY, Jung SN, Lim JS, Yoo G, Byeon JH. Dermatofibrosarcoma protuberans with pulmonary metastasis in the absence of local recurrence. Arch Plast Surg. 2012;39(3):265-267.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2024-04-27__at__11.45.35__AM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-149616.s20">
        <fig id="article-149616.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Dermatofibrosarcoma Protuberans, Right Lower Extremity. This image shows the tumor occupying the right popliteal and superoposterior tibial areas. Contributed by S Verma, MBBS, DVD, FRCP, FAAD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2024-04-27__at__11.44.02__AM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-149616.s21">
        <title>References</title>
        <ref id="article-149616.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshida</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Honma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>An unusual presentation of dermatofibrosarcoma protuberans: A case of fibrosarcomatous dermatofibrosarcoma protuberans with pleomorphic angiectatic tumor-like changes.</article-title>
            <source>J Cutan Pathol</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>51</volume>
            <issue>8</issue>
            <fpage>609</fpage>
            <page-range>609-613</page-range>
            <pub-id pub-id-type="pmid">38711216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vitiello</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma Protuberans: What Is This?</article-title>
            <source>Surg Clin North Am</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>102</volume>
            <issue>4</issue>
            <fpage>657</fpage>
            <page-range>657-665</page-range>
            <pub-id pub-id-type="pmid">35952694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Terrada</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jakacky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCarville</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Spunt</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bridge</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bahrami</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Primary intrathoracic dermatofibrosarcoma protuberans.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>1897</fpage>
            <page-range>1897-902</page-range>
            <pub-id pub-id-type="pmid">23108023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramirez-Fort</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Meier-Schiesser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Niaz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Niaz</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Feily</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fort</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Caba</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma Protuberans: The Current State of Multidisciplinary Management.</article-title>
            <source>Skinmed</source>
            <year>2020</year>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>288</fpage>
            <page-range>288-293</page-range>
            <pub-id pub-id-type="pmid">33160438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanabria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pinillos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chiesa-Estomba</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guntinas-Lichius</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>M&#x000e4;kitie</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Ferlito</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparing Mohs micrographic surgery and wide local excision in the management of head and neck dermatofibrosarcoma protuberans: a scoping review.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2024</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>2295816</fpage>
            <pub-id pub-id-type="pmid">38146660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jouary</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Beltran</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Plagnol</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taieb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ebran</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>P&#x000e9;deutour</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Delaunay</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma protuberans occurring in two brothers: Role of environmental or genetic factors?</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>57</volume>
            <issue>2 Suppl</issue>
            <fpage>S58</fpage>
            <page-range>S58-60</page-range>
            <pub-id pub-id-type="pmid">17637382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreicher</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Kurlander</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Gittleman</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Barnholtz-Sloan</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Bordeaux</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Incidence and Survival of Primary Dermatofibrosarcoma Protuberans in the United States.</article-title>
            <source>Dermatol Surg</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>42 Suppl 1</volume>
            <fpage>S24</fpage>
            <page-range>S24-31</page-range>
            <pub-id pub-id-type="pmid">26730971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laikova</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Oberemok</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Krasnodubets</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gal'chinsky</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Useinov</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Novikov</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Temirova</surname>
                <given-names>ZZ</given-names>
              </name>
              <name>
                <surname>Gorlov</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Shved</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Kumeiko</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Makalish</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Bessalova</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Fomochkina</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Esin</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Volkov</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kubyshkin</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs.</article-title>
            <source>Molecules</source>
            <year>2019</year>
            <month>Apr</month>
            <day>17</day>
            <volume>24</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">30999681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behroozan</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Glaich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma protuberans following tanning bed use.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2005</year>
            <season>Nov-Dec</season>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>751</fpage>
            <page-range>751-4</page-range>
            <pub-id pub-id-type="pmid">16302562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Behbahani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Samie</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with Mohs micrographic surgery in dermatofibrosarcoma protuberans of the head and neck: A cohort study.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2023</year>
            <month>Jun</month>
            <day>14</day>
            <fpage>1</fpage>
            <page-range>1-3</page-range>
            <pub-id pub-id-type="pmid">37436022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>KY</given-names>
              </name>
            </person-group>
            <article-title>Fibrosarcomatous Transformation in Dermatofibrosarcoma Protuberans of the Male Breast and its Association with Magnetic Resonance Imaging and Immunohistopathologic Features.</article-title>
            <source>Curr Med Imaging</source>
            <year>2024</year>
            <volume>20</volume>
            <fpage>e15734056309290</fpage>
            <pub-id pub-id-type="pmid">38757329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Billings</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stultz</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Procop</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Mirkin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vidimos</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma Protuberans: Update on the Diagnosis and Treatment.</article-title>
            <source>J Clin Med</source>
            <year>2020</year>
            <month>Jun</month>
            <day>05</day>
            <volume>9</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">32516921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saikia</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mandal</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Fibrosarcomatous change in the background of dermatofibrosarcoma protuberans in male breast: Study of a rare case and review of the entity.</article-title>
            <source>J Midlife Health</source>
            <year>2016</year>
            <season>Jan-Mar</season>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-8</page-range>
            <pub-id pub-id-type="pmid">27134483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bogucki</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Neuhaus</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hurst</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma protuberans: a review of the literature.</article-title>
            <source>Dermatol Surg</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>537</fpage>
            <page-range>537-51</page-range>
            <pub-id pub-id-type="pmid">22288484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bowne</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Antonescu</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Woodruff</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution.</article-title>
            <source>Cancer</source>
            <year>2000</year>
            <month>Jun</month>
            <day>15</day>
            <volume>88</volume>
            <issue>12</issue>
            <fpage>2711</fpage>
            <page-range>2711-20</page-range>
            <pub-id pub-id-type="pmid">10870053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Salti</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of surgery for dermatofibrosarcoma protuberans.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-5</page-range>
            <pub-id pub-id-type="pmid">15028319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gloster</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma protuberans.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>3 Pt 1</issue>
            <fpage>355</fpage>
            <page-range>355-74; quiz 375-6</page-range>
            <pub-id pub-id-type="pmid">8784271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Acosta</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>V&#x000e9;lez</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma Protuberans.</article-title>
            <source>Curr Treat Options Oncol</source>
            <year>2017</year>
            <month>Aug</month>
            <day>10</day>
            <volume>18</volume>
            <issue>9</issue>
            <fpage>56</fpage>
            <pub-id pub-id-type="pmid">28795284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Clinical Features, Pathological Findings and Treatment of Recurrent Dermatofibrosarcoma Protuberans.</article-title>
            <source>J Cancer</source>
            <year>2017</year>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>1319</fpage>
            <page-range>1319-1323</page-range>
            <pub-id pub-id-type="pmid">28607608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miceli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mussi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lo Vullo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lozza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Collini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Olmi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Gronchi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Oct</month>
            <day>20</day>
            <volume>23</volume>
            <issue>30</issue>
            <fpage>7669</fpage>
            <page-range>7669-75</page-range>
            <pub-id pub-id-type="pmid">16234529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Escobar</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Leite</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Barone</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Cartell</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dermoscopy of Dermatofibrosarcoma Protuberans: What Do We Know?</article-title>
            <source>Dermatol Pract Concept</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-145</page-range>
            <pub-id pub-id-type="pmid">31106017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khamdan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brailsford</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dirr</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sagut</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nietert</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Elston</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibroma Versus Dermatofibrosarcoma Protuberans: A Nuclear Morphology Study.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2023</year>
            <month>Sep</month>
            <day>01</day>
            <volume>45</volume>
            <issue>9</issue>
            <fpage>631</fpage>
            <page-range>631-634</page-range>
            <pub-id pub-id-type="pmid">37625803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navarrete-Dechent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nehal</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review.</article-title>
            <source>JAMA Dermatol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>155</volume>
            <issue>3</issue>
            <fpage>361</fpage>
            <page-range>361-369</page-range>
            <pub-id pub-id-type="pmid">30601909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ren</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shangguan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Imaging features of dermatofibrosarcoma protuberans.</article-title>
            <source>J Cancer Res Ther</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>476</fpage>
            <page-range>476-481</page-range>
            <pub-id pub-id-type="pmid">35645117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riggs</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McGuigan</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Samie</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Role of magnetic resonance imaging in perioperative assessment of dermatofibrosarcoma protuberans.</article-title>
            <source>Dermatol Surg</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>2036</fpage>
            <page-range>2036-41</page-range>
            <pub-id pub-id-type="pmid">19732100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rota</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Franza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fabbroni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paolini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Alessi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Padovano</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sanfilippo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>COL1A1::PDGFB fusion-associated uterine fibrosarcoma: A case report and review of the literature.</article-title>
            <source>Cancer Rep (Hoboken)</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>e1969</fpage>
            <pub-id pub-id-type="pmid">38279510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fionda</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Loperfido</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Stefani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lancellotta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Paradisi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Angeli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cappilli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caretto</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Zinicola</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schinzari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gentileschi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morganti</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Rembielak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tagliaferri</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The Role of Postoperative Radiotherapy in the Management of Dermatofibrosarcoma Protuberans: A Multidisciplinary Systematic Review.</article-title>
            <source>J Clin Med</source>
            <year>2024</year>
            <month>Mar</month>
            <day>21</day>
            <volume>13</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">38542022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xuejingzi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Quan</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans.</article-title>
            <source>Pan Afr Med J</source>
            <year>2019</year>
            <volume>33</volume>
            <fpage>297</fpage>
            <pub-id pub-id-type="pmid">31692830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>McHugh</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Folpe</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma Protuberans of Distal Extremities and Acral Sites: A Clinicopathologic Analysis of 27 Cases.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>413</fpage>
            <page-range>413-419</page-range>
            <pub-id pub-id-type="pmid">29240584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Sondak</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>600</fpage>
            <page-range>600-13</page-range>
            <pub-id pub-id-type="pmid">9344201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serra-Guill&#x000e9;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Llombart</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nagore</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guill&#x000e9;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sanmart&#x000ed;n</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Determination of Margins for Tumor Clearance in Dermatofibrosarcoma Protuberans: A Single-Center Study of 222 Cases Treated With Modified Mohs Surgery.</article-title>
            <source>Dermatol Surg</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-56</page-range>
            <pub-id pub-id-type="pmid">34743125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilder</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Crago</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Soft tissue tumors of the trunk: management of local disease in the breast and chest and abdominal walls.</article-title>
            <source>J Surg Oncol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>111</volume>
            <issue>5</issue>
            <fpage>546</fpage>
            <page-range>546-52</page-range>
            <pub-id pub-id-type="pmid">25418423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nieto-Benito</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Ciudad-Blanco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sanmartin-Jimenez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Garces</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Prieto</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vilarrasa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Eusebio-Murillo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mi&#x000f1;ano-Medrano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Escutia-Mu&#x000f1;oz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonzalez-Sixto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Artola-Igarza</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Alfaro Rubio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Redondo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Delgado-Jim&#x000e9;nez</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Schmidt</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Allende-Markixana</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Alonso-Pacheco</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Bracamonte</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de la Cueva Dobao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Navarro-Tejedor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suarez-Fern&#x000e1;ndez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carnero-Gonz&#x000e1;lez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez-Veiga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barchino-Ortiz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ruiz-Salas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Sambucety</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Estebaranz</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Botella-Estrada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feal-Cortizas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martorell Calatayud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gil</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Morales-Gordillo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Toll-Abell&#x000f3;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ocerin-Guerra</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mayor-Arenal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garcia-Donoso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cano-Martinez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sainz-Gaspar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Descalzo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Garcia-Doval</surname>
                <given-names>I</given-names>
              </name>
              <collab>REGESMOHS (Registro Espa&#x000f1;ol de Cirug&#x000ed;a de Mohs)</collab>
            </person-group>
            <article-title>Mohs micrographic surgery in dermatofibrosarcoma protuberans: Rate and risk factors for recurrence in a prospective cohort study from the Spanish Registry of Mohs Surgery (REGESMOHS) and review of the literature.</article-title>
            <source>Exp Dermatol</source>
            <year>2021</year>
            <month>May</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>717</fpage>
            <page-range>717-722</page-range>
            <pub-id pub-id-type="pmid">33523531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saiag</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grob</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lebbe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Malvehy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>del Marmol</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pehamberger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Peris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stratigos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Middelton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Basholt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Testori</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garbe</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline.</article-title>
            <source>Eur J Cancer</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>51</volume>
            <issue>17</issue>
            <fpage>2604</fpage>
            <page-range>2604-8</page-range>
            <pub-id pub-id-type="pmid">26189684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebede</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Dusza</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Busam</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Nehal</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Clinical value of paraffin sections in association with Mohs micrographic surgery for nonmelanoma skin cancers.</article-title>
            <source>Dermatol Surg</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>1631</fpage>
            <page-range>1631-8</page-range>
            <pub-id pub-id-type="pmid">22958072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Ad Hoc Task Force</collab>
              <name>
                <surname>Connolly</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Coldiron</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Storrs</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Vidimos</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Zalla</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith Begolka</surname>
                <given-names>W</given-names>
              </name>
              <collab>Ratings Panel</collab>
              <name>
                <surname>Berger</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Bigby</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bolognia</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Brodland</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cronin</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Grant-Kels</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hanke</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Hruza</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Lober</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>McBurney</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Roenigk</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Wheeland</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Wisco</surname>
                <given-names>OJ</given-names>
              </name>
            </person-group>
            <article-title>AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>531</fpage>
            <page-range>531-50</page-range>
            <pub-id pub-id-type="pmid">22959232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mullen</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma Protuberans: Wide Local Excision Versus Mohs Micrographic Surgery.</article-title>
            <source>Surg Oncol Clin N Am</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>827</fpage>
            <page-range>827-39</page-range>
            <pub-id pub-id-type="pmid">27591501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>ECS</given-names>
              </name>
              <name>
                <surname>Vyas</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Batbold</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Erwin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma Protuberans Recurrence After Wide Local Excision Versus Mohs Micrographic Surgery: A Systematic Review and Meta-Analysis.</article-title>
            <source>Dermatol Surg</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>479</fpage>
            <page-range>479-485</page-range>
            <pub-id pub-id-type="pmid">35353755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paradisi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abeni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rusciani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cigna</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wolter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scuderi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rusciani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kaufmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Podda</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>728</fpage>
            <page-range>728-36</page-range>
            <pub-id pub-id-type="pmid">18684568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lowe</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Onajin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Otley</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Arpey</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Roenigk</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>A Comparison of Mohs Micrographic Surgery and Wide Local Excision for Treatment of Dermatofibrosarcoma Protuberans With Long-Term Follow-up: The Mayo Clinic Experience.</article-title>
            <source>Dermatol Surg</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>98</fpage>
            <page-range>98-106</page-range>
            <pub-id pub-id-type="pmid">27749444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loghdey</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Varma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajpara</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Al-Rawi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Perks</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Mohs micrographic surgery for dermatofibrosarcoma protuberans (DFSP): a single-centre series of 76 patients treated by frozen-section Mohs micrographic surgery with a review of the literature.</article-title>
            <source>J Plast Reconstr Aesthet Surg</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>10</issue>
            <fpage>1315</fpage>
            <page-range>1315-21</page-range>
            <pub-id pub-id-type="pmid">25012249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crum</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>O'Hern</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Demer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Disease-Specific Mortality of Dermatofibrosarcoma Protuberans After Mohs Surgery Versus Wide Local Excision: A Systematic Review and Meta-Analysis.</article-title>
            <source>Dermatol Surg</source>
            <year>2024</year>
            <month>Apr</month>
            <day>01</day>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-321</page-range>
            <pub-id pub-id-type="pmid">38335454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Udkoff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beal</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Holzer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Brodland</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Knackstedt</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cost effectiveness of dermatofibrosarcoma protuberans treated with Mohs micrographic surgery compared with wide local excision.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>87</volume>
            <issue>5</issue>
            <fpage>1156</fpage>
            <page-range>1156-1157</page-range>
            <pub-id pub-id-type="pmid">35202774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massey</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Tok</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Strippoli</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Szabolcs</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Silvers</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Eliezri</surname>
                <given-names>YD</given-names>
              </name>
            </person-group>
            <article-title>A comparison of frozen and paraffin sections in dermatofibrosarcoma protuberans.</article-title>
            <source>Dermatol Surg</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>9</issue>
            <fpage>995</fpage>
            <page-range>995-8</page-range>
            <pub-id pub-id-type="pmid">9754088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Viehman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hitchcock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability.</article-title>
            <source>Dermatol Surg</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-9</page-range>
            <pub-id pub-id-type="pmid">8608381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snow</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Bagheri</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bentz</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Sable</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature.</article-title>
            <source>Cancer</source>
            <year>2004</year>
            <month>Jul</month>
            <day>01</day>
            <volume>101</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-38</page-range>
            <pub-id pub-id-type="pmid">15221986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sang&#x000fc;eza</surname>
                <given-names>OP</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma Protuberans.</article-title>
            <source>Dermatol Clin</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>483</fpage>
            <page-range>483-488</page-range>
            <pub-id pub-id-type="pmid">31466588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abbott</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nascimento</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>436</fpage>
            <page-range>436-43</page-range>
            <pub-id pub-id-type="pmid">16625088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mentzel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Beham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Katenkamp</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dei Tos</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance.</article-title>
            <source>Am J Surg Pathol</source>
            <year>1998</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>576</fpage>
            <page-range>576-87</page-range>
            <pub-id pub-id-type="pmid">9591728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdouh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boujguenna</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Soleh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abkari</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rais</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Navigating diagnostic challenges-distinguishing malignant melanoma and clear cell sarcoma of soft tissues: a case report and review of the literature.</article-title>
            <source>J Med Case Rep</source>
            <year>2024</year>
            <month>May</month>
            <day>17</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>249</fpage>
            <pub-id pub-id-type="pmid">38755643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Namikawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ogata</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jinnai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kambayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Asano</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Analysis of surgical margins and prognostic factors in dermatofibrosarcoma protuberans after wide local excision: A&#x000a0;multicenter study of 116 Japanese patients.</article-title>
            <source>J Dermatol</source>
            <year>2024</year>
            <month>Sep</month>
            <volume>51</volume>
            <issue>9</issue>
            <fpage>1225</fpage>
            <page-range>1225-1232</page-range>
            <pub-id pub-id-type="pmid">38775205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henry</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Platoff</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cerniglia</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Batchu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Sandilos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>YK</given-names>
              </name>
            </person-group>
            <article-title>Tyrosine kinase inhibitors versus radiation therapy in unresectable dermatofibrosarcoma protuberans (DFSP): A narrative systematic review.</article-title>
            <source>Am J Surg</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>225</volume>
            <issue>2</issue>
            <fpage>268</fpage>
            <page-range>268-274</page-range>
            <pub-id pub-id-type="pmid">36184329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castle</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Guadagnolo</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Zagars</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2013</year>
            <month>Jul</month>
            <day>01</day>
            <volume>86</volume>
            <issue>3</issue>
            <fpage>585</fpage>
            <page-range>585-90</page-range>
            <pub-id pub-id-type="pmid">23628134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Kirwan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dagan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mendenhall</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy for dermatofibrosarcoma protuberans.</article-title>
            <source>Am J Clin Oncol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>430</fpage>
            <page-range>430-2</page-range>
            <pub-id pub-id-type="pmid">23388563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haas</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Keus</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Le Pechoux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olmi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Poulsen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Seddon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where?</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2012</year>
            <month>Nov</month>
            <day>01</day>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>572</fpage>
            <page-range>572-80</page-range>
            <pub-id pub-id-type="pmid">22520481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salerno</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Alektiar</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Bedi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bradfield</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>DeLaney</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Folpe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XA</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stolten</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thorpe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trent</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Voermans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guadagnolo</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline.</article-title>
            <source>Pract Radiat Oncol</source>
            <year>2021</year>
            <season>Sep-Oct</season>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>339</fpage>
            <page-range>339-351</page-range>
            <pub-id pub-id-type="pmid">34326023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Turcotte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Catton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chabot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wunder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kandel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goddard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sadura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pater</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zee</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial.</article-title>
            <source>Lancet</source>
            <year>2002</year>
            <month>Jun</month>
            <day>29</day>
            <volume>359</volume>
            <issue>9325</issue>
            <fpage>2235</fpage>
            <page-range>2235-41</page-range>
            <pub-id pub-id-type="pmid">12103287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Turcotte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Catton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chabot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wunder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hammond</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kandel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goddard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sadura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pater</surname>
                <given-names>J</given-names>
              </name>
              <collab>Canadian Sarcoma Group</collab>
              <collab>NCI Canada Clinical Trial Group Randomized Trial</collab>
            </person-group>
            <article-title>Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma.</article-title>
            <source>Radiother Oncol</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-53</page-range>
            <pub-id pub-id-type="pmid">15948265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Catton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Fornasier</surname>
                <given-names>VL</given-names>
              </name>
            </person-group>
            <article-title>Preoperative and postoperative irradiation of soft tissue sarcomas: effect of radiation field size.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>1991</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>1595</fpage>
            <page-range>1595-9</page-range>
            <pub-id pub-id-type="pmid">1938569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>D&#x00119;biec-Rychter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nowecki</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Michej</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Symonides</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ptaszynski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ruka</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>264</fpage>
            <page-range>264-70</page-range>
            <pub-id pub-id-type="pmid">20569296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tassavor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Torbeck</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The various treatment modalities of dermatofibrosarcoma protuberans.</article-title>
            <source>Dermatol Online J</source>
            <year>2021</year>
            <month>Jun</month>
            <day>15</day>
            <volume>27</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">34387070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <article-title>Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration.</article-title>
            <source>Lancet</source>
            <year>1997</year>
            <month>Dec</month>
            <day>06</day>
            <volume>350</volume>
            <issue>9092</issue>
            <fpage>1647</fpage>
            <page-range>1647-54</page-range>
            <pub-id pub-id-type="pmid">9400508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pervaiz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Colterjohn</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Farrokhyar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tozer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Figueredo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghert</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.</article-title>
            <source>Cancer</source>
            <year>2008</year>
            <month>Aug</month>
            <day>01</day>
            <volume>113</volume>
            <issue>3</issue>
            <fpage>573</fpage>
            <page-range>573-81</page-range>
            <pub-id pub-id-type="pmid">18521899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grobmyer</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Demetri</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Mazumdar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riedel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.</article-title>
            <source>Ann Oncol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>1667</fpage>
            <page-range>1667-72</page-range>
            <pub-id pub-id-type="pmid">15520069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edmonson</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shiraki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frytak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parkinson</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.</article-title>
            <source>J Clin Oncol</source>
            <year>1993</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>1269</fpage>
            <page-range>1269-75</page-range>
            <pub-id pub-id-type="pmid">8315424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frustaci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gherlinzoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Paoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bonetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Azzarelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Comandone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olmi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Buonadonna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pignatti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Apice</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zmerly</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Serraino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Picci</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2001</year>
            <month>Mar</month>
            <day>01</day>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>1238</fpage>
            <page-range>1238-47</page-range>
            <pub-id pub-id-type="pmid">11230464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mack</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Schachar</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Kurien</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Temple</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Magi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>DeHaas</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Temple</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>646</fpage>
            <page-range>646-53</page-range>
            <pub-id pub-id-type="pmid">15965732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149616.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foshee</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Trofymenko</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Zeitouni</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>Surgical and Functional Considerations of Dermatofibrosarcoma Protuberans Involving Facial Nerve Danger Zones.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>39</fpage>
            <page-range>39-43</page-range>
            <pub-id pub-id-type="pmid">32038764</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
